Prophylaxis and antibiotic therapy in management protocols of patients treated with oral and intravenous bisphosphonates

Elena-Beatriz Bermúdez-Bejarano 1, María-Ángeles Serrera-Figallo 2, Aida Gutiérrez-Corrales 1, Manuel-Maria Romero-Ruiz 1, Raquel Castillo-de-Oyagüe 3, José-Luis Gutiérrez-Pérez 4, Daniel Torres-Lagares 4

1 Master’s Degree in Oral Surgery. School of Dentistry. University of Seville
2 Associate Professor. Integrated Dentistry and Patients with Special Diseases. School of Dentistry. University of Seville
3 Professor of Prostheses. Department of Stomatology. School of Dentistry. Complutense University of Madrid
4 Professor of Oral Surgery. School of Dentistry. University of Seville

Correspondence:
Dental School – University of Seville
C/ Avicena s/n 41009
Sevilla, SPAIN
danieltl@us.es

Received: 16/07/2016
Accepted: 01/10/2016

Abstract
Introduction: Osteonecrosis of the jaw (MRONJ) linked to bisphosphonate treatment has specific characteristics that render its therapeutic management challenging for clinicians. Poor response to standard treatment makes it essential to take special precautions when treating this type of disease; therefore, antibiotic prophylaxis and/or antibiotic therapy have been proposed as effective and helpful tools in these situations.

Objectives: This article seeks to assess published evidence in order to evaluate the different protocols used for antibiotic prophylaxis and/or antibiotic therapy in the general context of patients treated with bisphosphonates.

Material and Methods: A literature review of the last 10 years was carried out in PubMed using the following keywords: “antibiotic prophylaxis and osteonecrosis,” “bisphosphonates AND osteonecrosis AND dental management,” “bisphosphonate AND osteonecrosis AND antibiotic prophylaxis AND oral surgery.” A total of 188 articles were obtained, of which 18 were ultimately selected.

Results and Discussion: In patients treated with oral and intravenous bisphosphonates without chemotherapy-associated osteonecrosis of the jaw, antibiotic prophylaxis prior to oral surgery is an important tool to avoid osteonecrosis and promote healing of the affected area. If the patient previously exhibited chemotherapy-associated osteonecrosis after tooth extraction, antibiotic prophylaxis is indicated to prevent recurrent osteonecrosis and promote healing of the extraction site. If chemotherapy-associated osteonecrosis is already present, antibiotic therapy is a vital part of conservative management to reduce the symptomatology of MRONJ and keep it from worsening. Finally, a lack of clinical data and randomized controlled trials makes it difficult to choose the most appropriate protocol for the various clinical situations studied.

Key words: Bisphosphonates, antibiotic prophylaxis, maxillary osteonecrosis, antibiotic treatment.
Introduction

Antibiotic prophylaxis is used in dentistry to prevent infections in high-risk cases, such as during surgical procedures that enable pathogens to enter the body, or in patients whose general health characteristics or specific medical condition make them more susceptible to contracting new infections (1-5).

Consequently, prophylaxis is used to promote appropriate bioavailability of an antibiotic that can effectively tackle microorganisms and therefore prevent their proliferation and any subsequent infections. This concept is the opposite of antibiotic therapy, which is prescribed in cases of already established infection and is aimed at treating symptoms rather than preventing them (6).

Antibiotic prophylaxis and/or antibiotic therapy protocols have been established as an effective therapeutic tool in the prevention or conservative management of certain diseases. One such disease is chemotherapy-associated osteonecrosis of the jaw caused by bisphosphonates (or other drugs), described by Marx in 2003 (7) as an exposure of necrotic bone with more than eight weeks of evolution, associated with bisphosphonates and no prior radiation therapy. These lesions can progress and become infected or even suffer other complications, making them difficult to manage and with a wide range of therapies providing inconsistent results (8-10).

A distinction should be made between oral and intravenous routes of administration of bisphosphonates (11,12). Intravenous bisphosphonates are indicated for cancer patients (pamidronate and zoledronic acid); these are the most potent and are more likely to result in onset of MRONJ. They increase sevenfold the appearance of MRONJ after performing dental surgery, in comparison with oral bisphosphonates. In addition, it should be noted that the longer a treatment, the higher the risk of developing MRONJ, and larger doses also increase the risk of MRONJ. Intravenous bisphosphonates can remain in the blood for up to 10 years.

The onset of bisphosphonate-related MRONJ has also been correlated with different local factors (extractions, implant placement, periodontal disease, etc.) and systemic factors (endocrine disruptions, tobacco, alcohol, race, age, sex, etc.) (13,14).

In view of these risk factors, patient medical history, and the oral-systemic regions affected by bisphosphonates (including suppressed bone remodeling, deterioration of angiogenesis, toxicity of the soft tissues, modulatory dysfunction of the immune system, and delayed healing), there are many reasons to use antibiotic prophylaxis in patients treated with oral or intravenous bisphosphonates.

On the other hand, patients treated with oral or intravenous bisphosphonates who have already developed chemotherapy-associated osteonecrosis of the jaw may also benefit from antibiotic therapies to avoid potentially serious infection that can worsen symptoms; thus, antibiotic therapy can help improve overall clinical condition (15-17).

The present article seeks to identify the different published protocols of antibiotic prophylaxis and/or antibiotic therapy in patients treated with oral or intravenous bisphosphonates. To this end, a systematic review of the literature was carried out focusing on three clinical situations: a) patients treated with oral or intravenous bisphosphonates and without MRONJ who will undergo a dental extraction, b) patients treated with oral or intravenous bisphosphonates and with previous incidence of MRONJ who will undergo a dental extraction; and c) patients treated with oral or intravenous bisphosphonates and with MRONJ, as part of their conservative management.

Material and Methods

A review of the literature published in PubMed over the last 10 years was carried out using the following keywords: “antibiotic prophylaxis and osteonecrosis,” “bisphosphonates AND osteonecrosis AND dental management,” “bisphosphate AND osteonecrosis AND antibiotic prophylaxis AND oral surgery.” The results returned 29, 129, and 13 articles, respectively. The inclusion and exclusion criteria were then applied in order to fulfill the two proposed objectives.

The inclusion criteria for the first proposed objective (anti-biotic prophylaxis protocols) were: academic publications written in English that involved reviews of the literature, clinical trials, case control studies, cohorts studies and case series centered on antibiotic prophylaxis (indicating the antibiotic used, doses, time, and dosage used for treatment) in patients treated with oral or intravenous bisphosphonates, with or without antecedents of developing chemotherapy-associated osteonecrosis of the jaw, who were undergoing oral surgery.

The inclusion criteria for the second proposed objective (antibiotic treatment guidelines) were: academic publications written in English that involved reviews of the literature, clinical trials, or case series that specify the type of antibiotic used, doses and length of treatment, and guidelines used for antibiotic therapy in patients treated with oral and intravenous bisphosphonates with MRONJ, as part of their conservative management (therefore, antibiotics are used as part of patient treatment). The exclusion criteria for both proposed objectives were: articles that did not meet the eligibility requirements for both proposed objectives, articles unrelated to the research topic, articles that did not have an abstract or with an anonymous author, letters to the editor, and expert opinions.

The selection process was finished by manually searching through all the bibliographic references of the selected articles.
Results
The initial search in PubMed yielded 171 results, with an additional 17 articles identified during the manual search of the collected articles’ bibliographic references. The flow chart seen in figure 1 details how the eligibility criteria were applied. A total of 18 articles were selected for final inclusion in the present study. Results taken from the different articles can be seen in tables 1 to 3. Table 1 shows the antibiotic prophylaxis protocols applied to patients without previous MRONJ receiving treatment with oral bisphosphonates. The table also provides information on the antibiotic prophylaxis protocols used in patients without previous MRONJ receiving treatment with intravenous bisphosphonates. Table 2 is centered on antibiotic prophylaxis protocols in patients treated with oral or intravenous bisphosphonates who had previously had MRONJ. Lastly, Table 3, table 3 continue shows the antibiotic treatment protocols applied within a conservative management approach for patients with MRONJ receiving treatment with both oral and intravenous bisphosphonates.

When antibiotic prophylaxis is used in patients without previous MRONJ who are receiving treatment with oral bisphosphonates (Table 1), as well as in patients treated with intravenous bisphosphonates (Table 1), the most frequently used antibiotics are penicillin, amoxicillin, amoxicillin/clavulanic acid, metronidazole, and/or a combination thereof. Erythromycin, clindamycin, or even lincomycin are prescribed if the patient is allergic to penicillin or amoxicillin (15).

In the same way, the most widely used antibiotics for the treatment of MRONJ in patients taking oral bisphosphonates are penicillin, amoxicillin, amoxicillin/clavulanic acid, metronidazole, and/or a combination thereof.

With regard to the length of prophylactic antibiotic treatment prior to and following tooth extraction, there is no uniform approach applied in all patients receiving treatment with oral or intravenous bisphosphonates. Despite this, most authors agree that post-extraction treatment regimens in patients receiving oral and intravenous bisphosphonates should be continued until the surgical site has completely healed.

Fig. 1. Flow Chart.
Table 1. Antibiotic prophylaxis in patients treated with oral and intravenous bisphosphonates without previous MRONJ and who will undergo an extraction.

<table>
<thead>
<tr>
<th>Author/Year/ Type of study</th>
<th>Number of patients/ Average age</th>
<th>Number of and site of extractions</th>
<th>Oral Bisphosphonate: Treatment type, route of administration, time and number of patients</th>
<th>Causes for treatment with bisphosphonates and number of patients</th>
<th>Guidelines for antibiotic prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INTRAORAL BISPHOSPHONATES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lodi et al. 2010 (14) Prospective</td>
<td>23 patients Average age: 68.2 years</td>
<td>38 extractions Mand: 23 Max: 5 Both: 2</td>
<td>Clodronate PO: 1 Duration of BP: 17.5 months</td>
<td>Multiple myeloma: 11 Mammary Ca.: 8 Solid tumors: 2 Severe osteoporosis: 2</td>
<td>Amox 1g/18h x 20d 3 days before and 17 days after extraction</td>
</tr>
</tbody>
</table>
| Saia et al. 2010 (15) Prospective | 60 patients Average age: 65 years | 185 extractions Mand: 103 Max: 82 | Risedronate PO: 2 Duration of BP: ND | Metabolic bone diseases: 16 Multiple myeloma: 44 | Will be prescribed if: - there is no pain: 7 days after extraction - there is pain: 7 days before and after extraction  
Guideline to follow: Amox 1 g + Clavulanic acid 8h x 3d -Amox + Clavu ac. 1g/12h x 4d and Metro 500mg 8h x 4d - Allergy: Linco 500mg 12h x 7d |
| **INTRAVENOUS BISPHOSPHONATES** |                              |                                 |                                                                 |                                                                 |                                    |
| Lodi et al. 2010 (14) Prospective | 23 patients Average age: 68.2 years | 38 extractions Mand: 23 Max: 5 Both: 2 | Zoledronate IV: 20 Pamidronate IV: 1 Duration of BP: 17.5 months | Multiple myeloma: 11 Mammary Ca.: 8 Solid tumors: 2 Severe osteoporosis: 2 | Amox 1g/18h x 20d 3 days before and 17 days after extraction |
| Saia et al. 2010 (15) Prospective | 60 patients Average age: 65 years | 185 extractions Mand: 103 Max: 82 | Zoledronate IV: 38 Pamidronate IV: 15 Neridronate IV: 4 Duration of BP: ND | Metabolic bone diseases: 16 Multiple myeloma: 44 | Prescribed if: - there is no pain: 7 days after extraction - there is pain: 7 days before and after extraction  
Guideline to follow: Amox/Clavulanate potassium 1g 8h x 6d -Amox + Clavu ac. 1g/12h x 4d and Metro 500mg 8h x 4d - Allergy: Linco 500mg 12h x 7d |
| Scoletta et al. 2011 (16) Prospective | 64 patients Average age: 64.81 +/- 10.98 y | 220 extractions Mand: 113 Max: 107 | Zoledronate IV: 57 Pamidronate IV: 2 Zoled IV/Pam IV: 5 Duration of BP: 19.59 +/-18.95 months | Mammary Ca.: 32 Multiple myeloma: 21 Osteoporosis: 2 Prostate Ca.: 4 Other diseases: 3 Other cancers: 3 | Amox:Clavulanate potassium 1g 8h x 6d  
Allergy: Erythromycin 600mg 8h x 6d  
1 day before and 5 days after extraction |
| Ferlito et al. 2011 (17) Case series | 43 patients Average age: 56.4 y | 102 extractions Mand: 43 Max: 59 | Zoledronate IV Duration of BP: 16.2 +/- 3.2 months | Multiple myeloma: 28 Mammary Ca.: 8 Prostate Ca.: 5 Lung Ca.: 2 | Prophylaxis: Amox + Clavu ac. 1g/12 h  
2 days before and 5 days after extraction |
1 day before and 9 days after extraction |

Abbreviations: BP: Bisphosphonates; IV: Intravenous; PO: Oral; IM: Intramuscular; MRONJ: Osteonecrosis of the jaw; ND: Not documented; Ca.: Cancer; Metro: Metronidazole; Amox: Amoxicillin; Amox/Clavu ac.: Amoxicillin / Clavulanic Acid; Linco: Lincomycin; Erythro: Erythromycin; Clinda: Clindamycin; Peni: Penicillin.
Antibiotic therapy and bisphosphonates

Discussion
Antibiotic prophylaxis can be beneficial in avoiding the onset of MRONJ in patients who are set to undergo oral surgery (extraction) and are currently being treated with oral and intravenous bisphosphonates. If MRONJ has already developed and is under control, antibiotic treatment prophylaxis can prevent its recurrence. Moreover, antibiotic prophylaxis can help reduce the symptoms of osteonecrosis of the jaw, aiding in a conservative management regimen. However, despite the many studies found in the literature, there is no consensus on which is the most used antibiotic and its dosage (17).

The latest consensus of the American Association of Oral and Maxillofacial Surgeons (AAOMS) (18) refers to the use of antibiotics in the systemic management of such patients in Stage 0 (“Systemic management, including use of pain medication and antibiotics”). Given that the same article identifies this stage as a moment in which there is no clinical evidence of MRONJ, this kind of situation would be the first group of study of our article. Aside from this indication, consensus doesn’t detail the most useful antibiotics or that they should be used. For this reason, clinical experience collected in this review could be useful (18).

Antibiotics used in patients without previous MRONJ who are receiving treatment with oral bisphosphonates, as well as in patients treated with intravenous bisphosphonates (Table 1), have already been exposed in the Results section. With regard to the length of prophylactic antibiotic treatment prior to and following tooth extraction, there is no uniform approach applied in all patients receiving treatment with oral or intravenous bisphosphonates. Some articles indicate that antibiotics should be prescribed three (14) or seven (15) days before tooth extraction in patients treated with oral bisphosphonates.

Similarly, post-extraction recommendations vary, with articles suggesting that antibiotic prophylaxis be administered anywhere from seven (15) to seventeen days (14) post-intervention. For patients receiving treatment with intravenous bisphosphonates, the articles’ recommendations for when to begin pre-extraction prescription of antibiotics range from one, (16,19) two, (17) or three days before (14) to seven days before extraction (15). Post-extraction antibiotic treatment is recommended to be started five, (16-18) seven, (15,19) or seventeen days (14) after the procedure. Despite this, most authors agree that post-extraction treatment regimen in patients receiving oral and intravenous bisphosphonates should be continued until the surgical site has completely healed.

For the above reasons, the total length of treatment time can vary greatly. Patients treated with oral bisphosphonates can receive prophylaxis for anywhere from seven (15) to twenty days (14). In patients treated with intravenous bisphosphonates, treatment time can range from six (16) or seven (15,17) to twenty (14) days.

Regarding the use of antibiotics for the treatment of MRONJ, the consensus of the AAOMS (18) identifies as necessary from Stage 2, indicating that the isolated microorganisms are often sensitive to penicillin. Although it indicates a wide variety of antibiotics used to treat MRONJ not identify dose or temporal patterns, which if addressed in this paper, can help fill that consensus. No articles were found on administering antibiotic prophylaxis in patients receiving oral treatment with bisphosphonates who had also suffered previous osteonecrosis of the jaw and were set to undergo an extraction in the near future. Regarding patients undergoing intravenous bisphosphonate treatment, only one article was found, in which the authors prescribe amoxicillin before

Table 2. Antibiotic prophylaxis in patients treated with oral (0 articles) or intravenous bisphosphonates without previous MRONJ and who will undergo an extraction.

<table>
<thead>
<tr>
<th>Author/Year/Type of study</th>
<th>Number of patients/Average age</th>
<th>Number of and site of extractions</th>
<th>Treatment type, route of administration, number of patients</th>
<th>Causes for treatment with bisphosphonates and number of patients</th>
<th>Guidelines for antibiotic prophylaxis</th>
</tr>
</thead>
</table>
| Vescovi et al. 2015 (20) Prospective | 36 patients Average age: 68.5 y | 82 extractions Mand: 51 Max: 31 | 1. Zoledronate IV Duration of BP: 9-24 months 2. Multiple myeloma: 11 Osteoporosis: 7 Other cancers: 18 | Extraction prophylaxis: Amox 2g/d Management of MRONJ: Same treatment as before and Metro 1g/d 3 days before and 2 weeks after extraction |}

Abbreviations: BP Bisphosphonates; IV: Intravenous; PO: Oral; IM: Intramuscular; MRONJ: Osteonecrosis of the jaw; ND: Not documented; Ca.: Cancer; Metro: Metronidazole; Amox: Amoxicillin; Amox/Clavu ac.: Amoxicillin / Clavulanic Acid; Linco: Lincomycin; Erythro: Erythromycin; Clinda: Clindamycin; Peni: Penicillin.
<table>
<thead>
<tr>
<th>Author/Year/ Type of study</th>
<th>Number of patients/ Average age</th>
<th>Number of and site of extractions</th>
<th>Treatment type, route of administration, time and number of patients</th>
<th>Causes for treatment with bisphosphonates and number of patients</th>
<th>Antibiotic treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ORAL BISPHOSPHONATES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alons et al. 2009 [21]</td>
<td>7 patients Average age: 66.9 y</td>
<td>7 MRONJ Location: Mand: 5/ Max: 1/ Both: 1 Stages: ND</td>
<td>Clodronate PO: 1 Combination of BP: 3 Duration of BP: 48 months</td>
<td>Multiple myeloma: 1 Mammary Ca.: 2 Osteoporosis: 1 Combination of diseases: 1</td>
<td>6 million U Penicillin G + 1500mg Metro IV 1x a day x 1 week Fenticonil PO 1 x d = 1500mg Metro PO 1x a day x 2 weeks Allergy: 1800mg Clinda IV 1x a day x 1 week + 1800mg Clinda PO 1x a day x 3 weeks</td>
</tr>
<tr>
<td>Stanton et al. 2009 [22]</td>
<td>33 patients Average age: 64.5 y</td>
<td>33 MRONJ Location: Mand: 25/ Max: 8/ Both: 2 Stages: ND</td>
<td>Alendronate PO: 3 Combination of BP: 4 Duration of BP: ND</td>
<td>Mammary Ca.: 18 Multiple myeloma: 5 Prostate Ca.: 3 Non-Hodgkin's lymphoma 1 Osteoporosis: 4 Combination of diseases: 2</td>
<td>Before and after surgical intervention: Levo + Metro 4 weeks until complete healing Allergy to Levo: Metro or Peni</td>
</tr>
<tr>
<td>Ferlito et al. 2012 (23)</td>
<td>94 patients Average age: 66 y</td>
<td>94 MRONJ Location: ND Stages: Stage I: 8/ Stage II: 86</td>
<td>Oral Bisphosphonates: 16 Duration of BP: ND</td>
<td>Multiple myeloma: 4 Metastasis of prostate ca.: 8 Mammary Ca.: 1 Osteoporosis: 15 Paget’s disease: 2</td>
<td>Pre-surgical intervention: Stage I: Piperacillin/Tazobactam IM 2g/ 12h x 5d Stage II: Imipenem/Cilastatin IV 500mg 12h x 2d Post-surgical intervention: Stage I: Piperacillin/Tazobactam IM 2g/ 12h x 7d Stage II: Stage II: Imipenem/Cilastatin IV 500mg 12h x 3d</td>
</tr>
<tr>
<td>Williamson et al. 2010 (24)</td>
<td>40 patients Average age: 64 y</td>
<td>40 MRONJ Location: Mand: 25/ Both: 15 Stages: Refractory MRONJ</td>
<td>Ibandronate PO: 20 Alendronate PO: 12 Etidronate PO: 1 Risedronate PO: 3 Clodronate PO: 1 Combination of BP: 2 Duration of BP: 37.1 months</td>
<td>Mammary Ca.: 51 Prostate Ca.: 20 Plasmacytoma: 34 Renal Ca.: Lung Ca.: 8 Other cancers: 9 Other diseases: 2</td>
<td>Before surgical intervention: Amox 1g After surgical intervention: Amox 500mg 6h x 2weeks Allergy: Clinda 600mg before and after 450mg 6h x 2 weeks</td>
</tr>
<tr>
<td>Eckardt et al. 2011 (25)</td>
<td>142 patients Average age: 62 y</td>
<td>142 MRONJ Location: Mand: 82/ Max: 38 Both: 21 Stages: ND</td>
<td>Ibandronate PO: 20 Alendronate PO: 12 Etidronate PO: 1 Risedronate PO: 3 Clodronate PO: 1 Combination of BP: 2 Duration of BP: 37.1 months</td>
<td>Mammary Ca.: 51 Prostate Ca.: 20 Plasmacytoma: 34 Renal Ca.: Lung Ca.: 8 Other cancers: 9 Other diseases: 2</td>
<td>Pre- and post-surgical intervention: Peni and for allergies: Clinda</td>
</tr>
<tr>
<td>Vescovi et al. 2012 (26)</td>
<td>151 patients Average age: 66.6 y</td>
<td>139 MRONJ Location: Mand: 95/ Max: 42 Both: 14 Stages: Stage I: 24 Stage II: 102/ Stage III: 25</td>
<td>Alendronate PO: 16 Combination of BP: 29 Duration of BP: 48.2 months</td>
<td>Multiple myeloma: 56 Bone metastasis: 65 Osteoporosis: 30</td>
<td>Amox PO: 1g 8h x 2 weeks Metro PO: 250mg 12h x 2 weeks 3 days before and 10 days after surgical intervention</td>
</tr>
<tr>
<td>Eckert et al. 2007 (27)</td>
<td>24 patients Average age: 67 y</td>
<td>24 MRONJ Location: Mand: 16/ Max: 8 Stages: ND</td>
<td>Alendronate PO: 3 Ibandronate PO: 1 Combination of BP: 9 Duration of BP: 4-84 months</td>
<td>Mammary Ca.: 9 Multiple myeloma: 7 Prostate Ca.: 5 Lung Ca.: 1 Osteoporosis: 2</td>
<td>Antibiotic treatment: Amox + Clavu ac. 1 week</td>
</tr>
<tr>
<td>Junquera et al. 2009 (28)</td>
<td>21 patients Average age: 65.1 y</td>
<td>21 MRONJ Location: Mand: 17/ Max: 4 Stages: Stage I: 7/ Stage II: 9/ Stage III: 5</td>
<td>Alendronate PO: 1 Duration of BP: 11.2 months</td>
<td>Multiple myeloma: 5 Bone metastasis of Mammary Ca.: 13 Rheumatoid arthritis 1</td>
<td>Amox 2-4g per day + Clavu ac. 125-250mg per day x 2 weeks</td>
</tr>
</tbody>
</table>

Table 3. Antibiotic therapy as a conservative management in patients treated with oral and intravenous bisphosphonates with MRONJ.
the extraction and add metronidazole after the procedure (20). The pharmaceutical treatment began three days prior to the procedure and was continued for two weeks afterwards (18 days in total) (20).

Long-term antibiotic treatment appears to yield better results in regard to promoting proper healing of the alveolar sockets (17,20) and avoiding the onset of MRONJ. The most widely used antibiotics for the treatment of MRONJ in patients taking oral bisphosphonates are similar to the used in the first group of clinical situations:

Table 3 (continue). Antibiotic therapy as a conservative management in patients treated with oral and intravenous bisphosphonates with MRONJ.

<table>
<thead>
<tr>
<th>Epstein et al. 2010 (29) Case series</th>
<th>6 patients</th>
<th>Average age: 75 y</th>
<th>6 MRONJ Location: ND Stages: ND</th>
<th>Ibudronate PO: 1 Alendronate PO: 1 Duration of BP: ND</th>
<th>Cancer patients: 4 Osteoporosis: 2</th>
<th>Pentoxifylline and alpha-Tocopherol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eckert et al. 2007 (27) Case series</td>
<td>24 patients</td>
<td>Average age: 67 y</td>
<td>24 MRONJ Location: Mand: 16/ Max: 8 Stages: ND</td>
<td>Zoledronic acid IV: 9 Pamidronate IV: 2 Combination of BP: 9 Duration of BP: 4-84 months</td>
<td>Mammary Ca.: 9 Multiple myeloma: 7 Prostate Ca.: 5 Lung Ca.: 1 Osteoporosis: 2</td>
<td>Antibiotic treatment: Amox + Clavu ac. 1 week</td>
</tr>
<tr>
<td>Van De Wyngeart et al. 2008 (30) Case report</td>
<td>33 patients</td>
<td>Average age: 58 y</td>
<td>33 MRONJ Location: Mand: 17/ Max: 11/ Both: 5 Stages: Stage I: 9/ Stage II: 21/ Stage III: 3</td>
<td>Zoledronic acid IV: 21 Pamidronate IV: 6 Combination of BP: 27 Duration of BP: 27 months</td>
<td>Multiple myeloma: 9 Mammary Ca.: 19 Prostate Ca.: 7 Renal cell Ca.: 11</td>
<td>Amox + Clavu ac. 875/125mg Allergy: Clinda 300mg 8h x 10d Maintenance therapy: Doxi 100mg 1x a day x 3 weeks until complete healing</td>
</tr>
<tr>
<td>Alons et al. 2009 (21) Retrospective</td>
<td>7 patients</td>
<td>Average age: 66.9 y</td>
<td>7 MRONJ Location: Mand: 5/ Max: 1/ Both: 1 Stages: ND</td>
<td>Zoledronic acid IV: 3 Combination of BP: 3 Duration of BP: 48 months</td>
<td>Multiple myeloma: 1 Mammary Ca.: 2 Osteoporosis: 1 Combination of diseases: 1</td>
<td>Symptom treatment: 6 million U Penicillin G + 1500mg Metro 1x a day x 1 week IV</td>
</tr>
<tr>
<td>Saussez et al. 2009 (31) Retrospective</td>
<td>34 patients</td>
<td>Average age: 62 y</td>
<td>34 MRONJ Location: Mand: 18/ Max: 8/ Both: 7 Stages: Stage I: 7/ Stage II: 22/ Stage III: 5</td>
<td>Zoledronic acid IV: 21 Pamidronate IV: 3 Unknown: 1 Combination of BP: 9 Duration of BP: ND</td>
<td>Bone metastasis of mammary Ca.: 16 Prostate Ca.: 4 Other cancers: 5 Osteoporosis: 4</td>
<td>Amoxicillin or Amox/Clavu acid Allergy: Clinda or Doxi</td>
</tr>
<tr>
<td>Junquera et al. 2009 (28) Case series</td>
<td>21 patients</td>
<td>Average age: 65.1 y</td>
<td>21 MRONJ Location: Mand: 17/ Max: 4 Stages: Stage I: 7/ Stage II: 9/ Stage III: 5</td>
<td>Zoledronic acid IV: 19 Pamidronate IV: 1 Duration of BP: 11.2 months</td>
<td>Multiple myeloma: 5 Bone metastasis of mammary Ca.: 13 Rheumatoid arthritis: 3 Prostate Ca.: 2</td>
<td>Amox 2-4g per day + Clavu ac. 125-250mg a day x 2 weeks</td>
</tr>
<tr>
<td>Stanton et al. 2009 (22) Retrospective</td>
<td>33 patients</td>
<td>Average age: 64.5 y</td>
<td>33 MRONJ Location: Mand: 25/ Max: 8/ Both: 2 Stages: ND</td>
<td>Zoledronic acid IV: 26 Combination of BP: 4 Duration of BP: ND</td>
<td>Mammary Ca.: 18 Multiple myeloma: 5 Prostate Ca.: 3 Non-Hodgkin's lymphoma 1 Osteoporosis: 4 Combination of diseases: 2</td>
<td>Before and after surgical intervention: Levo + Metro 4 weeks until complete healing Allergy to Levo: Metro or Peni</td>
</tr>
<tr>
<td>Williamson et al. 2010 (24) Prospective</td>
<td>40 patients</td>
<td>Average age: 64 y</td>
<td>40 MRONJ Location: Mand: 25/ Both: 15 Stages: Refractory MRONJ</td>
<td>Bisphosphonates IV: 24 Duration of BP: ND</td>
<td>Multiple myeloma: 2 Metastasis of prostate Ca.: 8 Mammary Ca.: 2 Osteoporosis: 15 Paget’s disease 2</td>
<td>Before surgical intervention: Amox 1g After surgical intervention: Amox 500mg 4x a day x 2weeks Allergy: Clinda 600mg before and after 450mg 4 a d x 2 weeks</td>
</tr>
</tbody>
</table>
Table 3 (continue-1). Antibiotic therapy as a conservative management in patients treated with oral and intravenous bisphosphonates with MRONJ.

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Study Type</th>
<th>Patients</th>
<th>Average age</th>
<th>Location</th>
<th>Stages</th>
<th>Duration of BP</th>
<th>Combination of BP</th>
<th>Metastasis of lung Ca.</th>
<th>Bone metastasis</th>
<th>Bone metastasis:</th>
<th>Multi myeloma:</th>
<th>Two groups and different guidelines:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferlin et al. 2012 (23)</td>
<td>Case series</td>
<td>94 patients</td>
<td>66 y</td>
<td>ND</td>
<td>Stage I: 8/ Stage II:</td>
<td>Zoledronic acid IV: 72</td>
<td>Piperacillin/Tazobactam</td>
<td>Clindamycin IM: 1</td>
<td>Neridronate IV: 4</td>
<td>Duration of BP: 24 months</td>
<td>Pre-surgical intervention: Stage I: Piperacillin/Tazobactam 2g/12h × 5d IM</td>
<td>Post-surgical intervention: Stage I: Piperacillin/Tazobactam 2g/12h × 7d IM Stage II: Stage II: Imapenem/Cilastatin 500mg 12h × 2d IV</td>
</tr>
<tr>
<td>Vescovi et al. 2012 (26)</td>
<td>Case series</td>
<td>151 patients</td>
<td>66.6 y</td>
<td>Mand: 95/ Max: 42/ Both: 14</td>
<td>Zoledronic acid IV: 87</td>
<td>Pamidronate IV: 2</td>
<td>Multiple myeloma: Amox PO: 1g 3 x d × 2 weeks</td>
<td>Bone metastasis: Moxiflox, Doxi and Metro</td>
<td>Duration of BP: 48.2 months</td>
<td>3 days before and 10 days after surgical intervention</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BP: Bisphosphonates; IV: Intravenous; PO: Oral; IM: Intramuscular; MRONJ: Osteonecrosis of the jaw; ND: Not documented; Ca.: Cancer; Met: Metronidazole; Amox: Amoxicillin, Amox/Clav: Amoxicillin / Clavulanic acid, Linco: Lincomycin, Erythro: Erythromycin, Clinda: Clindamycin, Peni: Penicillin; Levo: Levofloxacin; Doxi: Doxycyclin; A-ST: Short-term preoperative antibiotic regime; B-LT: Long-term preoperative antibiotic regime.

penicillin, amoxicillin, amoxicillin/clavulanic acid, metronidazole, and/or a combination thereof. There are also studies that prescribed penicillin G + IV metronidazole, (21) levofloxacin + metronidazole, (22) piperacillin + tazobactam, or imipenem + cilastatin (23). If the patient is allergic to penicillin or amoxicillin, clindamycin is usually prescribed instead (21,24-26,30-32).

There is no consensus on total treatment time. Authors’ recommendations for conservative management of MRONJ using antibiotics include one week, (27) ten days, (26) fifteen days (24,26,28,29), or three or four weeks, until the healing process is complete (21,22). Most of the consulted studies agree that antibiotic treatment should be long-term. This is because depending on the severity of MRONJ, conservative treatment may be accompanied by surgical treatments with varying levels of invasiveness. Consequently, antibiotic therapy is often continued long-term until the clinical remission of signs and symptoms linked to MRONJ or its surgical treatment.

In patients treated with intravenous bisphosphonates, the most commonly used antibiotics are penicillin, amoxicillin, amoxicillin/clavulanic acid, metronidazole, and/or a combination thereof. Some studies also prescribed penicillin G + IV metronidazole, (21) levofloxacin + metronidazole, (22) piperacillin + tazobactam, or imipenem + cilastatin (23). If the patient is allergic to penicillin or amoxicillin, clindamycin is usually prescribed instead (21,24-26,30-32).

No consensus exists on total treatment times, with the approach being similar to treatments described for patients undergoing treatment with oral bisphosphonates. In any case, it is always best to carry out antibiogram before prescribing any antibiotics; (12) however, broad spectrum antibiotics can be used in cases where MRONJ must be treated as soon as possible.

Sparse clinical data and a lack of randomized controlled trials make it impossible to definitively identify the most appropriate protocol for each of the different clinical situations studied (33,34).

In conclusion, it is clear that in patients being treated with oral and intravenous bisphosphonates who have not had prior chemotherapy-associated osteonecrosis of the jaw, the use of antibiotic prophylaxis prior to oral surgery is an important tool in avoiding osteonecrosis and in promoting proper healing of the affected area. If a patient previously had chemotherapy-associated osteonecrosis after a tooth extraction, antibiotic prophylaxis will be indicated to prevent the recurrence of osteonecrosis and to promote healing of the extraction site.
chemotherapy-associated osteonecrosis is already present, antibiotic therapy is a vital part of conservative management to reduce the symptomatology of MRONJ and keep it from worsening.

References

Conflict of Interest
The authors have declared that no conflict of interest exist.